医学
挽救疗法
鼻咽癌
放射治疗
内科学
肿瘤科
比例危险模型
外科
作者
Ting Liu,Bo-Wen Shen,Li-Ting Liu,Zhen-Chong Yang,Shi-Qian Wang,Da-Feng Lin,Xue-Song Sun,Shan-Shan Guo,Sai-Lan Liu,Mei-Juan Luo,Qiu-Yan Chen,Lin-Quan Tang,Hai-Qiang Mai
标识
DOI:10.1016/j.radonc.2021.12.046
摘要
Abstract
Background
Salvage radiotherapy (RT) is a potentially curative approach for advanced locally recurrent nasopharyngeal carcinoma (NPC), but it is associated with severe toxicities. We aimed to develop a model to predict which patients would benefit from salvage RT. Methods
A total of 809 patients who were diagnosed with advanced locally recurrent NPC and treated with salvage RT or palliative chemotherapy (CT) at a high-volume cancer center were included. Patients were randomly split into a training and validation set and matched using inverse probability of treatment weighting. The primary outcome was overall survival (OS). Candidate variables associated with heterogeneous treatment effects were identified with interaction terms in Cox model and incorporated into Salvage Radiotherapy Outcome Score (SARTOS). Results
The final model included five interaction terms indicating that female sex, presence of prior RT-induced grade ≥ 3 late toxicities and suboptimal performance status were associated with less benefit from salvage RT. SARTOS from the model significantly predicted treatment effects of salvage RT in matched training (Pinteration < 0.001) and validation cohorts (Pinteration = 0.027). Of patients in high SARTOS subgroup, salvage RT significantly improved survival versus palliative CT in matched training (3-year OS 67.3% vs. 42.0%, HR 0.51, 95% CI 0.32–0.82, P = 0.005) and validation cohorts (3-year OS 71.8% vs. 22.8%, HR 0.40, 95% CI 0.17–0.97, P = 0.042); in low SARTOS subgroup, salvage RT failed to induce survival benefit. Conclusions
We found that the SARTOS model could identify a subgroup of patients who benefit from salvage RT versus palliative CT, which helps personalize treatment recommendations for patients with recurrent NPC.
科研通智能强力驱动
Strongly Powered by AbleSci AI